trial · primary record
silevertinib in combination with temozolomide
Glioblastoma (GBM)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 162 |
| Primary completion | 2029-03 |
| Primary endpoint | Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT07326566 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:14.110Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07326566
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.